In a report released today, Matthew Weston from UBS maintained a Hold rating on Novartis AG, with a price target of CHF95.00. The company’s shares opened today at CHF106.36.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Weston is a 4-star analyst with an average return of 9.0% and a 75.90% success rate. Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and Sanofi.
In addition to UBS, Novartis AG also received a Hold from Bank of America Securities’s Sachin Jain in a report issued on September 26. However, on October 7, Barclays maintained a Sell rating on Novartis AG (Six Swiss: NOVN).
NOVN market cap is currently CHF202.7B and has a P/E ratio of 17.81.
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan
- Generics to be excluded from Trump’s pharma tariff plan, WSJ reports
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)